Equities

OpGen Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

OpGen Inc

Actions
  • Price (USD)34.00
  • Today's Change6.00 / 21.43%
  • Shares traded4.08k
  • 1 Year change+2,733.33%
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2026 20:41 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

  • Revenue in USD (TTM)9.00m
  • Net income in USD6.70m
  • Incorporated2001
  • Employees1.00
  • Location
    OpGen Inc9717 Key West Avenue, Suite 100ROCKVILLE 20850United StatesUSA
  • Phone+1 (301) 869-9683
  • Fax+1 (301) 869-9684
  • Websitehttps://opgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Palisade Bio Inc0.00-11.23m257.78m8.00--4.91-----2.98-2.980.000.35220.00----0.00-137.67-130.84-221.20-165.85-------31,830.91---1,041.550.0616---100.00---17.38------
Crescent Biopharma Inc0.00-55.96m260.41m4.00--1.17-----21.97-21.970.008.400.00----0.00-72.70-55.66-86.54-62.83-------2,068.09----0.00---100.00---2.66---41.45--
Neurogene Inc0.00-85.13m263.33m107.00--0.9459-----4.12-4.120.0017.970.00----0.00-37.67-27.58-40.40-29.44-------28,431.03----0.0001-------106.91---1.67--
Avalo Therapeutics Inc192.00k-99.70m264.94m23.00--2.85--1,379.88-8.79-8.790.01695.140.0017----8,347.83-89.35-94.60-128.95-128.3154.6981.11-52,019.79-790.66---9.830.0248---77.08-42.05-11.37------
Nautilus Biotechnology Inc0.00-62.81m267.77m124.00--1.58-----0.4982-0.49820.001.340.00----0.00-27.27-20.34-28.36-20.82------------0.00-------11.16--18.04--
Minerva Neurosciences Inc0.00-14.03m273.06m8.00---------1.85-1.850.00-4.940.00----0.00-39.57-35.73-44.01-37.64-------263.85----2.36------104.80------
Aardvark Therapeutics Inc0.00-48.77m274.56m33.00--2.24-----2.53-2.530.005.630.00-------44.96---47.90--------------0.00-------185.63------
Larimar Therapeutics Inc0.00-132.00m276.69m65.00--2.05-----1.93-1.930.001.620.00----0.00-64.96-45.05-76.53-50.22------------0.00-------118.15---7.58--
OpGen Inc9.00m6.70m284.18m1.0042.5227.7641.2431.580.65850.65850.88941.010.994--4.429,000,000.0075.58-74.7181.77-111.02100.0030.7976.04-602.64----0.00--52.018.23134.76------
Rezolute Inc0.00-77.18m284.67m71.00--1.90-----0.9291-0.92910.001.620.00----0.00-54.73-47.11-58.50-49.55------------0.00-------8.70------
Relmada Therapeutics Inc0.00-56.17m294.80m17.00--14.10-----1.80-1.800.000.28520.00----0.00-159.13-77.37-195.99-84.69------------0.00------19.04------
Armata Pharmaceuticals Inc5.05m-46.90m295.99m60.00------58.57-1.30-1.300.1396-2.640.0538--3.3984,233.34-49.96-47.36---60.79-----928.00-829.99---2.122.88--14.24--72.60--53.02--
Prenetics Global Ltd66.32m-40.67m302.29m285.00--1.50--4.56-3.10-3.545.0114.260.30684.8317.70232,698.60-20.40-60.40-25.34-81.5348.0140.86-66.49-385.992.51-3.830.0129--40.8327.1014.76--23.29--
CytoDyn Inc0.00-40.35m310.48m13.00---------0.0322-0.03220.00-0.09460.00----0.00-229.87-225.45-----------184,742.10---6.09--------104.41------
Data as of Feb 11 2026. Currency figures normalised to OpGen Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.